NexVas™ Alzheimer's Disease

This past decade scientists have made enormous strides in understanding how Alzheimer’s disease (AD) affects the brain. Many of these recent insights point toward promising new strategies for treatment. Resverlogix’s new discovery research program is dedicated to ApoA-I production and its therapeutic potential for disorders that effect cognitive function such as AD. Both epidemiological and mechanistic evidence indicates that there exists a link between low ApoA-I/HDL and neurodegenerative disease such as Alzheimer’s. Resverlogix has potent molecules that are able to selectively increase ApoA-I production that may beneficially impact AD. The Alzheimer’s program will be developed in RVX Therapeutics’, a wholly owned subsidiary of Resverlogix Corp.

Every 72 seconds someone will develop Alzheimer’s disease. Neurodegenerative diseases such as Alzheimer’s are one of the most debilitating in the developed world. There are now more than 5 million people in the United States who are living with Alzheimer’s. It is estimated that in the United States the prevalence of the disease may to grow to 15 million people 2050. In a report commissioned by the Alzheimer’s Association, caregiver costs in the United States are estimated at US$36.5 billion which includes loss of productivity, absenteeism and worker replacement. The indirect costs of AD would also be greatly reduced; it is estimated that one-half to two-thirds of the cost of AD care stems from unpaid caregivers (often family members), who spend 16-35 hours per week looking after a person with AD. These figures underscore the importance of developing new therapies to aide in the socioeconomic burden of AD.